GlassScriptPhysician profile
Katherine Krueck
NPI 1568457273
$785.56
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Pediatric Emergency Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $119.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $117.29 | 2019-2020 | |
| Pfizer INC. | $97.15 | 2019 | |
| Tris Pharma INC | $91.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $68.10 | 2019-2020 | |
| Hologic Sales and Service, LLC | $56.46 | 2019-2020 | |
| Kaleo, INC. | $54.83 | 2019-2020 | |
| Sanofi Pasteur INC. | $52.16 | 2019 | |
| Glaxosmithkline, LLC. | $48.12 | 2019 | |
| Cranial Technologies, INC | $44.80 | 2019-2020 | |
| Neos Therapeutics, LP | $44.09 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $38.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.17 | 2019 | |
| Circassia INC. | $14.77 | 2019 | |
| Shire North American Group INC | $13.22 | 2019 | |
| Adlon Therapeutics L.P. | $13.01 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $12.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Krueck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.